ABUS logo

Arbutus Biopharma (ABUS) Company Overview

Profile

Full Name:

Arbutus Biopharma Corporation

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

July 26, 2007

Indexes:

Not included

Description:

Arbutus Biopharma (ABUS) is a biotechnology company focused on developing treatments for viral infections, particularly hepatitis B. They work on innovative therapies to improve patient outcomes and aim to advance their drug candidates through clinical trials to bring new options to the market.

Events Calendar

Earnings

Next earnings date:

Mar 12, 2025

Recent quarterly earnings:

Nov 6, 2024

Recent annual earnings:

Feb 29, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Nov 4, 2010

Analyst ratings

Recent major analysts updates

Jan 21, 25 HC Wainwright & Co.
Buy
Nov 20, 24 Chardan Capital
Buy
Nov 18, 24 HC Wainwright & Co.
Buy
Nov 7, 24 HC Wainwright & Co.
Buy
Nov 7, 24 Chardan Capital
Buy
Sep 5, 24 Jefferies
Buy
Aug 2, 24 JMP Securities
Market Outperform
Jun 7, 24 HC Wainwright & Co.
Buy
Jun 6, 24 HC Wainwright & Co.
Buy
Jun 5, 24 Chardan Capital
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

FAQ

  • What is the ticker symbol for Arbutus Biopharma?
  • Does Arbutus Biopharma pay dividends?
  • What sector is Arbutus Biopharma in?
  • What industry is Arbutus Biopharma in?
  • What country is Arbutus Biopharma based in?
  • When did Arbutus Biopharma go public?
  • Is Arbutus Biopharma in the S&P 500?
  • Is Arbutus Biopharma in the NASDAQ 100?
  • Is Arbutus Biopharma in the Dow Jones?
  • When was Arbutus Biopharma's last earnings report?
  • When does Arbutus Biopharma report earnings?
  • Should I buy Arbutus Biopharma stock now?

What is the ticker symbol for Arbutus Biopharma?

The ticker symbol for Arbutus Biopharma is NASDAQ:ABUS

Does Arbutus Biopharma pay dividends?

No, Arbutus Biopharma does not pay dividends

What sector is Arbutus Biopharma in?

Arbutus Biopharma is in the Healthcare sector

What industry is Arbutus Biopharma in?

Arbutus Biopharma is in the Biotechnology industry

What country is Arbutus Biopharma based in?

Arbutus Biopharma is headquartered in United States

When did Arbutus Biopharma go public?

Arbutus Biopharma's initial public offering (IPO) was on July 26, 2007

Is Arbutus Biopharma in the S&P 500?

No, Arbutus Biopharma is not included in the S&P 500 index

Is Arbutus Biopharma in the NASDAQ 100?

No, Arbutus Biopharma is not included in the NASDAQ 100 index

Is Arbutus Biopharma in the Dow Jones?

No, Arbutus Biopharma is not included in the Dow Jones index

When was Arbutus Biopharma's last earnings report?

Arbutus Biopharma's most recent earnings report was on Nov 6, 2024

When does Arbutus Biopharma report earnings?

The next expected earnings date for Arbutus Biopharma is Mar 12, 2025

Should I buy Arbutus Biopharma stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions